Insulin resistance and diabetes mellitus

Journal of Diabetes and its Complications

Volumn 10, Issue 5, 1996, Pages 243-245

  DeFronzo, Ralph A ^a   Del Prato, Stefano ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENFLUOREX; INSULIN;

DIABETES MELLITUS; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0030578874     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/1056-8727(96)00046-3     Document Type: Article

References (28)

1. 1. DeFronzo RA: Lilly lecture. The triumvirate: beta cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667-687, 1988.
2. 2. Reaven GM: Banting lecture. Role of insulin resistance in human disease. Diabetes 37:1594-1607, 1988.
3. 3. Gulli G, Ferrannini E, Stern M, Haffner S, DeFronzo RA: The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes 41:1575-1586, 1992.
4. 4. Lillioja S, Mott D, Zawadzki J, Young A, Abbott W, Knowler W, Bennett P, Mott P, Bogardus C: In vivo insulin action is a familial characteristic in nondiabetic Pima Indians. Diabetes 36:1329-1335, 1987.
5. 5. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991.
6. 6. Ferrannini E, Haffner SM, Mitchell BD, Stern MP: Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34:416-422, 1991.
7. 7. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S: Insulin resistance in essential hypertension. N Engl J Med 317:350-357, 1987.
8. 8. Natali A, Sontoro D, Palombo C, Cerri M, Ghione S, Ferrannini E: Impaired insulin action on skeletal muscle metabolism in essential hypertension. Hypertension 17: 170-178, 1991.
9. 9. Taskinen MR: Lipoprotein lipase in diabetes. Diabetes Metab Rev 3:551-570, 1987.
10. 10. Kannel WB: Lipids, diabetes, and coronary heart disease: Insight from the Framingham study. Am Heart J 110:1100-1107, 1985.
11. 11. Laasko M, Sarlund H, Mykkanen L: Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 10:223-231, 1990.
12. 12. Stout RW: Insulin as a mitogenic factor: role in the pathogenesis of cardiovascular disease. Am J Med 90: 62S-65S, 1991.
13. 13. Cruz AB, Amatuzio DS, Grande F, Hay LJ: Effect of intraarterial insulin on tissue cholesterol and fatty acids in alloxan-diabetic dogs. Circ Res 9:39-43, 1961.
14. 14. Duff GL, McMillan GC: The effect of alloxan diabetes on experimental cholesterol atherosclerosis in the rabbit. I. The inhibition of experimental cholesterol atherosclerosis in alloxan diabetes. II. The effect of alloxan diabetes on the retrogression of experimental cholesterol atherosclerosis. J Exp Med 89:611-629, 1949.
15. 15. Bressler P, Bailey S, Saad R, DeFronzo RA: Insulin resistance and coronary artery disease: The missing link, Diabetes 41(suppl 1):24A, 1992.
16. 16. Bressler P, DeFronzo RA: Drugs and diabetes. Diabetes Rev 2:53-84, 1994.
17. 17. Henry RR, Gumbiner B: Benefits and limitations of very-low-caloric diet therapy in obese NIDDM. Diabetes Care 14:802-823, 1991.
18. 18. Koivisto VA, DeFronzo RA: Physical training and insulin sensitivity. Diabetes Metab Rev 1:445-481, 1986.
19. 19. Groop LC: Sulfonylureas in NIDDM. Diabetes Care 15: 737-754, 1992.
20. 20. DeFronzo RA, Goodman AM: Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. New Engl J Med 333:541-549, 1995.
21. 21. DeFronzo RA, Barzilai N, Simonson DC: Mechanisms of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 73: 1294-1301, 1991.
22. 22. Shank M, Del Prato S, DeFronzo RA: Bedtime insulin/daytime glipizide: effective therapy for sulfonylurea failures in NIDDM. Diabetes 44:165-172, 1995.
23. 23. Arnaud O, Nathan C: Antiobesity and lipid-lowering agents with anti-diabetic activity, in Bailey CJ, Flatt PR (eds), New Antidiabetic Drugs, London, Smith-Gordon; 1990, pp. 133-142.
24. 24. Geelen MJ: Mechanisms responsible for the inhibitory effects of benfluorex on hepatic intermediary metabolism. Biochem Pharmacol 32:1765-1772, 1983.
25. 25. Storlein LH, Oakes ND, Pan DA, Kusunoki M, Jenkins AB: Syndrome of insulin resistance in the rat: Inducement by diet and amelioration with benfluorex. Diabetes 42:457-462, 1993.
26. 26. De Feo P, Lavielle R, De Gregoris P, Bolli GB: Anti-hyperglycemic mechanisms of benfluorex in type II diabetes mellitus. Diabetes Metab Rev 9 (suppl 1):35S-41S, 1993.
27. 27. Riccio A, Vigili de Kreutzenberg S, Dorella M, De Biasi L, Marescotti MC, Tiengo A, Del Prato S: Mechanism(s) of the blood glucose lowering action of benfluorex. Diabetes Metab Rev 9 (suppl 1):19S-27S, 1993.
28. 28. Bianchi R, Bongers V, Bravenboer B, Erkelens DW: Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. Diabetes Care 16:557-559, 1993.